Authorization reinforces Alberta company’s role in advancing innovative animal health solutions for emerging veterinary challenges
Calgary, Alberta – August 06, 2026 – Alberta Vet Labs Ltd. (AVL Solvet) welcomes the U.S. Food and Drug Administration’s (FDA) Emergency Use Authorization (EUA) for Ivermectin Liquid for Horses for the short-term prevention of New World Screwworm (NWS) infestations in horses. AVL Solvet is the sponsor of the authorized product, marking an important milestone in the company’s commitment to delivering innovative veterinary health solutions that respond to emerging industry needs.
The July 15, 2026, authorization comes as veterinarians and animal health officials work to address the growing threat posed by New World screwworm, providing an additional preventive tool to help protect equine health under the conditions outlined in the FDA’s Emergency Use Authorization.
“This milestone reflects what we set out to achieve when we founded Solvet in 2009,” said Dr. Merle Olson, AVL Solvet Founder and Director of Research & Development. “We believed there was an opportunity to build an innovative Canadian veterinary pharmaceutical company capable of responding to emerging animal health challenges. Seeing that our vision contributes to an issue as important as New World Screwworm is incredibly rewarding, and we remain committed to developing solutions that help protect animal health for years to come.”
Founded in Alberta, AVL Solvet has built its reputation by identifying gaps in the veterinary pharmaceutical landscape and developing practical, science-driven solutions that help veterinarians and producers respond to evolving animal health challenges. The FDA’s authorization further demonstrates the company’s ability to bring innovative products to market while supporting animal health in Canada, the United States, and beyond.
The authorization also reflects Solvet’s continued growth as an Alberta success story. Through ongoing investment in innovation and manufacturing, the company is expanding its capacity to develop and produce veterinary pharmaceuticals that support both domestic and international markets.
“Last week’s announcement is an exciting milestone for Solvet and reinforces the impact an Alberta-based company can have in addressing global animal health challenges,” said Lionel Gibbs, CEO of Solvet. “Our planned facility expansion represents the next chapter of that journey, allowing us to scale our manufacturing capacity, accelerate innovation, and bring more veterinary solutions to market. We’re committed to growing our impact while continuing to support veterinarians, protect animal health, and strengthen agricultural industries across North America.”
The company is pursuing strategic growth initiatives to significantly expand its manufacturing and development capabilities, positioning Solvet to accelerate innovation and respond more effectively to future animal health challenges. This expanded capacity will enable the company to broaden its product portfolio, strengthen supply resilience, and deliver even greater value to veterinarians and producers across the industry.
The FDA’s Emergency Use Authorization underscores the important role that innovative veterinary pharmaceutical companies can play in supporting animal health during rapidly evolving circumstances. Solvet remains committed to advancing science-based solutions that help protect animal health while meeting the changing needs of veterinarians and producers.
Link to the US Food and Drug Administration bulletin: FDA Issues Emergency Use Authorization for Drug for Short-Term Prevention of New World Screwworm in Horses
Detailed product information about Ivermectin Liquid for Horses can be found in the Fact Sheet: Emergency Use Authorization of Ivermectin Liquid for Horses (ivermectin oral solution) for New World Screwworm (NWS).
FOR MORE INFORMATION:
Lionel Gibbs, Chief Executive Officer, Solvet
(403) 392-0158
lionel.gibbs@avetlabs.com
ABOUT SOLVET: Founded by the Olson family in 2009, Solvet meets the veterinary pharmaceutical needs of producers and pet owners. With an innovative business model, they develop products by listening to customers and producing them at their headquarters in Calgary, Alberta, Canada. www.solvet.ca
